The world awaits a COVID-19 cure. Learn how Israel has mobilized its scientific and technological talents to overcome this modern-day plague, featuring:
- Yaky Yanai, CEO of Pluristem Therapeutics (NASDAQ: PSTI) is working on a placenta-based cell therapy treatment for respiratory and inflammatory complications associated with COVID-19.
- Vered Kaplan, CEO of Orgenesis, (NASDAQ: ORGS) a global biotech company, is unlocking the potential of cell and gene therapy including anti-viral technologies relevant for COVID-19 to provide life changing personalized medical treatments at the point-of-care to patients.
- Dr. Mark Levitt, Medical Director from RedHill Biopharma (Nasdaq: RDHL) a specialty biopharmaceutical company, is working on an experimental drug, Opaganib, which has shown anti-viral and anti-inflammatory properties to help reduce lung inflammation in COVID-19 patients.
Zoom information will be given upon registration. For more information contact, firstname.lastname@example.org.
Sponsored by the Maryland/Israel Development Center